COMMUNIQUÉS West-GlobeNewswire

Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
22/05/2026
FLORHAM PARK, N.J., May 22, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on commercializing and developing novel treatments for gastrointestinal (GI) [...]
American Shared Hospital Services Announces Annual Shareholder Meeting to be Held on June 24, 2026
22/05/2026
SAN FRANCISCO, May 22, 2026 (GLOBE NEWSWIRE) -- American Shared Hospital Services (NYSE American: AMS) (the "Company"), a leading provider of stereotactic radiosurgery equipment and advanced radiation therapy cancer [...]
Enable Injections Announces CE Certification of the enFuse® On-Body Delivery System for Use with Aspaveli® Distributed by Sobi
22/05/2026
Regulatory milestone expands access to wearable, patient-centric drug delivery for rare disease treatment across Europe CINCINNATI, May 22, 2026 (GLOBE NEWSWIRE) -- Enable Injections, Inc. (“Enable”), a healthcare [...]
Black Diamond Therapeutics to Participate in Jefferies Global Healthcare Conference
22/05/2026
CAMBRIDGE, Mass., May 22, 2026 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in [...]
CHMP issues positive opinion for JASCAYD® (nerandomilast), bringing a new IPF and PPF therapy closer to patients in the EU
22/05/2026
Not intended for US and UK media Idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) are life-threatening, progressive lung conditions that require early and sustained intervention 1,2 CHMP’s [...]
Medicenna Announces the Filing of its Prospectus Supplement and Investment Term Sheet
22/05/2026
Base shelf prospectus is accessible on SEDAR+ NOT FOR DISSEMINATION INTO THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES TORONTO and HOUSTON, May 22, 2026 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp [...]
Anavex Life Sciences Receives Expected Nasdaq Delinquency Notification
22/05/2026
NEW YORK, May 22, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for central [...]
BriaCell Presentations Highlight Positive Clinical Data for Bria-IMT™ at ASCO 2026
22/05/2026
Final Phase 2 Bria-IMT median overall survival (OS) is 16.6 months (with Phase 3 formulation) Positive Quality of Life (QOL) data from the ongoing Phase 3 study in heavily pre-treated metastatic breast cancer (MBC) [...]
Oncolytics Biotech® to Present Data at ASCO 2026 Reinforcing Pelareorep’s Potential Across Gastrointestinal Tumors
22/05/2026
Translational data demonstrate induction of both innate and adaptive antiviral and anti-tumor specific immune responses capable of controlling tumor growth SAN DIEGO, May 22, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech [...]
AC Immune Presents New Phase 1 Data Indicating Higher Uptake of TDP-43 PET Tracer ACI-19626 in Patients with ALS
22/05/2026
AC Immune Presents New Phase 1 Data Indicating Higher Uptake of TDP-43 PET Tracer ACI-19626 in Patients with ALS Presentation at 2026 TDP43 Summit shows ACI-19626 detects TDP-43 pathology in patients with amyotrophic [...]
Assembly Biosciences Announces Expansion of ABI-6250 Clinical Development Into Cholestatic Liver Diseases
22/05/2026
– Phase 2 study in cholestatic liver diseases, focused on PBC and PSC, anticipated to initiate in Q1 2027 – – Builds on completed Phase 1a study and ongoing development in HDV – SOUTH SAN FRANCISCO, Calif., May 22, 2026 [...]
Arch Biopartners announces Royal Columbian Hospital has dosed its first patient in its Phase II cardiac surgery-associated AKI trial
22/05/2026
TORONTO, May 22, 2026 (GLOBE NEWSWIRE) -- Arch Biopartners Inc . (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) announced today that Royal Columbian Hospital (RCH) has dosed its first patient in the [...]
Cartigenix HP® Backed by Three Human Studies as Clinicians Seek Evidence-Based Joint Health Options
22/05/2026
For decades, supplement research has not supported cartilage regeneration. A randomized, placebo-controlled study in Pharmaceutical Research documented measurable cartilage regeneration biomarkers at 90 days, a [...]
BioStem Technologies Announces $2.5 Million Private Placement Financing with its First Institutional Investor
22/05/2026
Strengthening balance sheet on path to Nasdaq uplisting POMPANO BEACH, Fla., May 22, 2026 (GLOBE NEWSWIRE) -- BioStem Technologies Inc. (OTC: BSEM), a leading regenerative medicine company focused on the development, [...]
Repligen Corporation to Present at William Blair 46th Annual Growth Stock Conference
22/05/2026
WALTHAM, Mass., May 22, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will participate in the William Blair [...]
2026 ASCO | Pivotal Data of InnoCare's Novel BCL2 Inhibitor Mesutoclax Released
22/05/2026
BEIJING, May 22, 2026 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the abstracts [...]
BioNTech to Showcase Progress Across Late-Stage Oncology Pipeline at the 2026 ASCO Annual Meeting
22/05/2026
Pumitamig data from the ongoing Phase 2/3 ROSETTA Lung-02 trial in first-line non-small cell lung cancer mark the third global data set to consistently show encouraging anti-tumor activity for pumitamig in combination [...]
STORM Therapeutics to Present Promising Phase 1 Sarcoma Data Demonstrating Activity of First‑in‑Class METTL3 Inhibitor STC‑15 at ASCO 2026
22/05/2026
Subset analysis shows early clinical activity supported by biomarker evidence of targeting cancer stem cell pathways driving tumor growth and progression CAMBRIDGE, United Kingdom, May 22, 2026 (GLOBE NEWSWIRE) -- STORM [...]
China approves HERNEXEOS® as first targeted oral treatment option for HER2-mutant advanced NSCLC at initial diagnosis
22/05/2026
Not intended for UK and US media Therapy approved based on Phase Ib Beamion LUNG-1 trial data, demonstrating robust efficacy (75.7% objective response rate) in treatment-naïve patients 1 Expedited approval as an initial [...]

Pages